PIK3CG and breast neoplasm: The PI3K/AKT/mTOR and RAS/MAPK/ERK pathways are related to the resistance to endocrine treatments in breast tumors [25] and the PI3K/AKT/mTOR pathway always activated in HER2+ tumors [33].